Search Within

Hamza Hashmi

Formats
  1. Meeting Abstract (41)
  2. Journal Article (9)
  3. Research Letter (3)
  4. Review (2)
  5. Correspondence (1)
  6. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (26)
  2. Department of Medicine (26)
  3. Hematologic Malignancies, Division of (26)
  4. Bone Marrow Transplant (25)
  5. Myeloma (25)
  6. Survivorship Research (25)

More Groups

People
  1. Sridevi Rajeeve (27)
  2. Saad Usmani (26)
  3. Sham Mailankody (25)
  4. Alexander Lesokhin (23)
  5. Carlyn Rose Tan (23)
  6. Heather Landau (23)

More People

Years
  1. 2025 (5)
  2. 2024 (52)
Publications
  1. Blood (27)
  2. Clinical Lymphoma, Myeloma and Leukemia (16)
  3. Blood Cancer Journal (3)
  4. Blood Advances (2)
  5. European Journal of Haematology (2)
  6. British Journal of Haematology (1)

More Publications

Publishers
  1. American Society of Hematology (29)
  2. Elsevier Inc. (17)
  3. John Wiley & Sons (3)
  4. Nature Publishing Group (3)
  5. Biomed Central Ltd (1)
  6. Frontiers Media S.A. (1)

More Publishers

Results (57)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TACTUM: Trends in access to cellular therapies in multiple myeloma, perspectives of treating versus referring physicians
    Journal Article

    Atallah, R.; Ahmed, N.; Ayoobkhan, F.; Saif, M. S. I.; Logan, E.; Shrestha, A.; Anwer, F.; Mahmoudjafari, Z.; Mushtaq, M. U.; Hashmi, H.; more...
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • "Fast but not so furious": A condensed step-up dosing schedule of teclistamab for relapsed/refractory multiple myeloma
    Journal Article

    Graf, K. C.; Davis, J. A.; Cendagorta, A.; Granger, K.; Gaffney, K. J.; Green, K.; Hess, B. T.; Hashmi, H.
    eJHaem (2024)

    Fulltext@MSK | Save
  • Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
    Journal Article

    Zanwar, S.; Sidana, S.; Shune, L.; Puglianini, O. C.; Pasvolsky, O.; Gonzalez, R.; Dima, D.; Afrough, A.; Kaur, G.; Davis, J. A.; more...
    Journal of Hematology & Oncology (2024)

    Fulltext@MSK | Save
  • Impact of extraosseous extramedullary disease on outcomes of patients with relapsed-refractory multiple myeloma receiving standard-of-care chimeric antigen receptor T-cell therapy
    Journal Article

    Dima, D.; Abdallah, A. O.; Davis, J. A.; Awada, H.; Goel, U.; Rashid, A.; DeJarnette, S.; Anwer, F.; Shune, L.; Raza, S.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy
    Editorial

    Davis, J. A.; McGann, M.; Marini, J.; Hashmi, H.
    Expert Review of Anticancer Therapy (2024)

    Fulltext@MSK | Save
  • Beyond BCMA: The next wave of CAR T cell therapy in multiple myeloma
    Review

    Miller, K.; Hashmi, H.; Rajeeve, S.
    Frontiers in Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naìˆve relapsed multiple myeloma
    Journal Article

    Dima, D.; Mansour, R.; Davis, J. A.; Minchak, M.; Goel, U.; Atallah, R.; Logan, E.; Tabak, C.; Rashid, A.; Ahmed, N.; more...
    European Journal of Haematology (2024)

    Fulltext@MSK | Save